A company presentation will take place during the conference’s Innovation track on Friday, March 28th at 9:00am. NeauxCancer conference’s Innovation track spotlights the most promising emerging ...

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

Among a group of heavily pretreated aGvHD patients who were not responding to steroid therapies or had become dependent on them, MaaT013 was associated with an OS rate of 54% at six months ...

以下文章来源于Springer Healthcare，作者Springer Healthcare2025年3月8日，全球血液学领域权威期刊Bone Marrow Transplantation (BMT) ...

国际竞争格局中，美国FDA批准的6款MSCs药物主要集中于移植物抗宿主病和退行性关节炎。中国企业的弯道超车策略聚焦于工艺创新，天士力开发的冻干复苏技术使细胞活性保持率突破95%，运输稳定性从72小时延长至15天，这为产品商业化奠定了关键基础。

currently in an ongoing Phase Ib trial for patients with acute Graft-versus-Host Disease (aGvHD). The company also has multiple I&I assets in the pre-clinical stage. Dr. Xiaohu (Jason) Zhang ...

currently in an ongoing Phase Ib trial for patients with acute Graft-versus-Host Disease (aGvHD). The company also has multiple I&I assets in the pre-clinical stage. Dr. Xiaohu (Jason) Zhang, ...

for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients 2 months and older and key upcoming milestones for its late-stage pipeline. ”We are committed to making ...

RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart ...